Clinical Trials

1,350 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06898957 2026-04-22

(DeLLphi-310)

200 enrolled

Phase 1/2 Active not recruiting

Small Cell Lung Carcinoma

NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT05771480 2026-04-21

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT06992609 2026-04-21

ALBORAN

70 enrolled

Small Cell Lung Carcinoma

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Phase 1/2 Active not recruiting

Urothelial Cancer

NCT02734004 2026-04-20

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT06780137 2026-04-20

MK-6070-002

Phase 1/2 Recruiting

262 enrolled

Small Cell Lung Carcinoma

NCT06890598 2026-04-20

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07391670 2026-04-17

IMFINZI-subQ

Phase 1 Recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT05450692 2026-04-16

LATIFY

594 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05925530 2026-04-16

MDT-BRIDGE

142 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06467357 2026-04-16

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT06746116 2026-04-16

DUoENDE

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT07005128 2026-04-16

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT03778957 2026-04-15

EMERALD-1

724 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06117891 2026-04-15

REFINE-IO

Recruiting

300 enrolled

Phase 1 Not yet recruiting

Unresectable Hepatocellular Carcinoma

NCT07531095 2026-04-15

DeLLphi-313

160 enrolled

Small Cell Lung Carcinoma

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT06667908 2026-04-14

CONVERGE

Phase 2 Recruiting

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

304 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07195695 2026-04-08

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05301842 2026-04-07

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02087423 2026-04-06

ATLANTIC

Phase 2 Completed

446 enrolled 23 charts

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04612751 2026-04-06

TROPION-Lung04

155 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07361497 2026-04-06

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Phase 2 Recruiting

60 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast

Breast Neoplasms

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06008093 2026-03-30

TRITON

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Urinary Bladder Neoplasms

NCT05063565 2026-03-27

ROWAN

100 enrolled

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03298451 2026-03-20

HIMALAYA

1,324 enrolled 31 charts 2 FDA

Carcinoma, Hepatocellular

NCT03875235 2026-03-19

TOPAZ-1

810 enrolled 24 charts 2 FDA

Biliary Tract Neoplasms

NCT06040099 2026-03-19

EMERALD-Y90

58 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast

Breast Neoplasms

NCT06606847 2026-03-18

LADOGA

30 enrolled